FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity

2003/06/01 by Olivier Barbier, Inès Pineda‐Torra, Ines Pineda Torra +11 · 29 citations
Medicine · Pharmacology, Toxicology and Pharmaceutics · Biochemistry, Genetics and Molecular Biology · #Drug Transport and Resistance Mechanisms #Pharmacogenetics and Drug Metabolism #Retinoids in leukemia and cellular processes

paper · doi:10.1016/s0016-5085(03)00388-3

Cited by

• Establishing Transcriptional Signatures to Differentiate PXR-, CAR-, and AhR-Mediated Regulation of Drug Metabolism and Transport Genes in Cryopreserved Human Hepatocytes
• Pharmaco-nutraceutical improvement of the response to obeticholic acid with omega-3 polyunsaturated fatty acids
• The Janus face of phase II drug-metabolizing enzymes in hypoxia: guardian of antioxidant defense or accomplice in metabolic disorders?
• REGULATION OF DRUG-METABOLIZING ENZYMES AND TRANSPORTERS IN INFLAMMATION
• Lithocholic acid decreases expression of UGT2B7 in Caco-2 cells: a potential role for a negative farnesoid X receptor response element. [europepmc]
• New perspectives for the treatment of cholestasis: lessons from basic science applied clinically. [europepmc]
• Regulation of FXR transcriptional activity in health and disease: Emerging roles of FXR cofactors and post-translational modifications. [europepmc]
• A signature of balancing selection in the region upstream to the human UGT2B4 gene and implications for breast cancer risk. [europepmc]
• Farnesoid X receptor represses hepatic human APOA gene expression. [europepmc]
• FXR signaling in the enterohepatic system. [europepmc]
• Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective. [europepmc]
• Nuclear receptor control of enterohepatic circulation. [europepmc]
• Nutritional lipidomics: molecular metabolism, analytics, and diagnostics. [europepmc]
• FXR-induced secretion of FGF15/19 inhibits CYP27 expression in cholangiocytes through p38 kinase pathway. [europepmc]
• Peroxisome proliferator-activated receptor α activates human multidrug resistance transporter 3/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion. [europepmc]
• Nuclear bile acid signaling through the farnesoid X receptor. [europepmc]
• Fibrates and cholestasis. [europepmc]
• Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. [europepmc]
• Bile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer. [europepmc]
• Nuclear Receptor Metabolism of Bile Acids and Xenobiotics: A Coordinated Detoxification System with Impact on Health and Diseases. [europepmc]
• Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer. [europepmc]
• Bile Acid Signaling in Neurodegenerative and Neurological Disorders. [europepmc]
• Potential role of drug metabolizing enzymes in chemotherapy-induced gastrointestinal toxicity and hepatotoxicity. [europepmc]
• Liver macrophages and inflammation in physiology and physiopathology of non-alcoholic fatty liver disease. [europepmc]
• Distinct Bile Acid Profiles in Patients With Chronic Hepatitis B Virus Infection Reveal Metabolic Interplay Between Host, Virus and Gut Microbiome. [europepmc]
• Enterohepatic and non-canonical roles of farnesoid X receptor in controlling lipid and glucose metabolism. [europepmc]
• The role of bile acids in carcinogenesis. [europepmc]
• PPARα: A potential therapeutic target of cholestasis. [europepmc]
• Gut Microbiome-Linked Metabolites in the Pathobiology of Major Depression With or Without Anxiety-A Role for Bile Acids. [europepmc]